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Abst rac t
Background and purpose: Despite the rapid development
of neuropharmacotherapy, medical treatment of neuropathic
pain (NP) still constitutes a significant socioeconomic prob-
lem. The authors herein present a group of patients treated
with motor cortex stimulation (MCS) for NP of various types
and aetiologies.
Material and methods: Our cohort included 12 female and
11 male NP patients aged 53 ± 16 treated with MCS.
Eleven patients were diagnosed with neuropathic facial pain
(NFP), 8 with hemi-body neuropathic pain (HNP), and 
4 with deafferentation pain (DP). Prior to surgery, 16 out
of 23 patients were treated with repetitive transcranial mag-
netic stimulation (rTMS), with a positive response in 10 cas-
es. Pain intensity in our group was evaluated with the visual
analogue scale (VAS) one month before and three months
after MCS implantation.
Results: Improvement on the VAS was reported in the whole
group of patients (p < 0.001). The best results were report-
ed in the NFP group (p < 0.001) while the worst ones were
noted in the DP group (p = 0.04). Anamnesis duration po -
sitively correlated with outcome. Infection forced the authors
to permanently remove the system in one case. There were
no other complications in the group.
St reszczenie
Wstêp i cel pracy: Pomimo dynamicznego rozwoju neuro-
farmakoterapii, leczenie bólów neuropatycznych stanowi istot-
ny problem socjoekonomiczny. Autorzy przedstawiaj¹ grupê
chorych leczonych metod¹ stymulacji kory ruchowej (motor
cortex stimulation – MCS) z powodu bólów neuropatycznych
o ró¿nym obrazie klinicznym i etiologii.
Materia³ i metody: W grupie 12 kobiet oraz 11 mê¿czyzn
w wieku 53 ± 16 lat zastosowano MCS z powodu bólu neu-
ropatycznego. U 11 chorych rozpoznano neuropatyczne bóle
twarzy, u 8 chorych po³owiczy ból neuropatyczny, a u 4 cho-
rych – ból deaferentacyjny. U 16 chorych przeprowadzono
próbn¹ przezczaszkow¹ stymulacjê magnetyczn¹, uzyskuj¹c
przejœciow¹ poprawê u 10 z nich. Nasilenie dolegliwoœci bólo-
wych oceniano z wykorzystaniem wzrokowej skali analogowej
(visual analogue scale – VAS) miesi¹c przed implantacj¹ oraz
w trzecim miesi¹cu po implantacji MCS.
Wyniki: U wszystkich chorych w grupie stwierdzono popra-
wê mierzon¹ VAS (p < 0,001). Najlepsze efekty leczenia bólu
neuropatycznego zaobserwowano w grupie chorych z neuro-
patycznym bólem twarzy (p < 0,001), a najs³absze u chorych
z rozpoznanym bólem deaferentacyjnym (p = 0,04). D³u -
goœæ wywiadów korelowa³a dodatnio z wynikami leczenia.
U jednego chorego ze wzglêdu na zaka¿enie usuniêto system
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Introduction
The ‘decade of the brain’ without any doubts posi-
tively influenced the development of neuropharma-
cotherapy. Unfortunately, the efficacy of neuropathic
pain treatment, regardless of contemporary, conserva-
tive treatment modalities, is unsatisfactory for a signi -
ficant percentage of patients. Neuropathic pain arises
from peripheral, central or sympathetic nervous system
injury. It has been estimated that neuropathic pain affects
3% of the general population while being the leading
cause of disability for as many as 30% of cancer patients
and an additional 10% of patients following radio-
and/or chemotherapy. Neuropathic pain is usually con-
stant, burning and often with related dysaesthesia.
Mechanic or thermal allodynia is usually present with
concomitant hypoaesthesia or anaesthesia. Patients
describe neuropathic pain as a sensation of burning,
stinging or pulling, sometimes even like a viper bite.
A significant number of patients have a considerable
autonomic component of neuropathic pain. Neuropathic
pain might have focal character, encompassing single
dermatomes (e.g. peripheral neuropathic pain, phantom
pain), or might cover large regions (e.g. thalamic pain)
[1-3]. Its pathophysiology is unclear. Melzack and Wall
in 1965 proposed a control gate theory that only par-
tially explains the mechanism of neuropathic pain.
Accordingly, a disinhibition of afferent nociceptive
impulsation at the level of posterior horns of the spinal
cord, brainstem or midbrain results in a constant per-
ception of pain in the given body region.
The history of neuromodulation implementation in
the treatment of neuropathic pain reaches back to
the 1950s. The attempts to instigate ablative techniques,
similarly to the deep brain structures, in the treatment
of neuropathic pain furnished unsatisfactory results.
Conversely, deep brain stimulation results in an improve-
ment in a selected group of neuropathic pain patients,
but still the implantation procedure, especially when
compared to motor cortex stimulation (MCS), is bur-
dened by a high risk of complications. Moreover, side
effects that often coexist with a favourable analgesic
effect significantly diminished its popularity. The intro-
duction of cortical stimulators raised hope for a quality
of life improvement for patients with NP. The attempts
of sensory cortex stimulation rendered little if any of
the expected results, often worsening the symptoms.
The introduction of MCS by Meyerson and Tsubokawa
in 1991 and 1993, however, resulted in significant ame-
lioration of symptoms for the majority of patients [4-10].
The mechanism of MCS action is not known, and
the role of activation of the thalamus, cingulate gyrus,
fronto-orbital cortex, brainstem and periaqueductal gray
matter present in positron emission tomography during
stimulation is unclear [8]. Fifteen years after the intro-
duction of MCS, the efficacy of neuropathic pain treat-
ment with this modality still increases while the neces-
sity for trial external stimulation that lasts for weeks
diminished over the years owing to the introduction
of neuronavigation, elaboration of proper functional
magnetic resonance imaging (fMRI) protocols and im -
plementation of intraoperative somatosensory and motor
evoked potentials [11-13].
The authors present a group of patients with diag-
nosed neuropathic pain of various aetiologies treated
with MCS. The aim of the study is to evaluate the effi-
cacy and safety of MCS in neuropathic pain.
Material and methods
Twelve women and 11 men with neuropathic pain
aged 53 ± 16 years were implanted with MCS devices.
Anamnesis in our group varied from 2 to 32 years (mean
12 years).
Eleven patients (9 women and 2 men) were diagnos -
ed with neuropathic facial pain (NFP). In 3 patients,
NFP followed thalamic stroke, in 4 cases it resulted
from craniofacial surgery (posttraumatic in 3 patients
Conclusions: Minimally invasive, safe neuromodulative treat-
ment with MCS permits neuropathic pain control with good
efficacy. The type of neuropathic pain might be a prognostic
factor.
Key words: neuropathic pain, cortical stimulation, transcra-
nial magnetic stimulation.
i nie podejmowano próby ponownego wszczepienia. Innych
powik³añ w grupie nie stwierdzano.
Wnioski: Wykorzystanie minimalnie inwazyjnych technik
neuromodulacyjnych, w tym MCS, pozwala na skuteczne i bez-
pieczne zmniejszenie nasilenia bólów neuropatycznych. Rodzaj
bólu neuropatycznego mo¿e mieæ znaczenie rokownicze. 
S³owa kluczowe: bóle neuropatyczne, stymulacja kory rucho-
wej, przezczaszkowa stymulacja magnetyczna.
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and related to benign neoplasm in 1 patient) and in 
4 patients it occurred as a complication of ablative treat-
ment for trigeminal neuralgia. Eight patients underwent
transcranial magnetic stimulation (rTMS) that result-
ed in pain reduction in 6 patients. Pain intensity was
assessed with the visual analogue scale (VAS) and aver-
aged 8 (7-9.5). 
Hemi-body neuropathic pain (HNP) was diagnosed
in 8 patients (6 men and 2 women), including 5 patients
with thalamic stroke and 3 patients with spinal cord
injury. All of the patients underwent rTMS that result-
ed in pain reduction in 4 patients. Pain intensity was
evaluated with the VAS scale with average intensity
of 8.5 (7-9.5).
Four patients (3 men and 1 woman) presented with
deafferentation pain (DP) of the upper extremity fol-
lowing avulsion injury of the brachial plexus. No rTMS
was implemented. Again, pain intensity was evaluated
with the VAS scale with average intensity of 8 (7.5-9.5).
In 16 patients in our cohort, trial rTMS was perfor -
med that resulted in transient improvement in 10 patients,
which was recognized as a positive prognostic factor.
Prior to surgery, MRI was performed in all of the pa -
tients. Based on imaging studies cortical structures in
axial, sagittal and coronal planes were identified. Func-
tional MRI was simultaneously performed in order to
identify the regions of the motor cortex relevant for
the salient pain.
Surgery was performed under general anaesthesia
following preoperative planning with a neuronavigation
system that allowed identification of the region of the
motor cortex relevant for the given pain type. Fronto-
parietal craniotomy was followed by implantation of ele -
ctrodes (either two four-contact electrodes or one eight-
contact electrode). Intraoperative somatosensory and
motor evoked potentials were assessed in 16 patients in
order to confirm electrodes’ localization. Then the sys-
tem was internalized and electrodes were fixed to the
dura. A stimulating electrode was subsequently connect -
ed to the stimulator with an interconnecting electrode
and a whole system was internalized (Itrel 3 or Syner-
gy, Medtronic). Stimulation amplitude was then in creas -
ed over the first 24 hours after surgery and aimed at sub-
threshold values for the motor response of 20-50 Hz
frequency, 60-200 ms impulse width and stimulation
times of 30-120 minutes in 1-6 cycles per 24 hours.
Pain intensity was evaluated with the VAS scale
a month prior to and 3 months after initiation of sti mu -
lation.
Statistical analysis
Nominal or ordinal scale variables are presented as
percentages with 95% confidence interval (95% CI).
Continuous variables with normal or close to normal
distribution are presented as the arithmetic mean with
95% CI. For continuous variables with distribution 
significantly different from normal, we used either me -
dian or mean with range. Distribution plots represent
single observations along with linear regression with
95% CI. The size of a given data point expresses the
number of observations in a given arrangement of val-
ues (large point for 2 and very large point for 3 identi-
cal observations).
NFP HNP DP
NFP – neuropathic facial pain; HNP – hemi-body neuropathic pain; DP – deafferentation pain
VAS – visual analogue scale
Fig. 2. Efficacy of motor cortex stimulation (MCS) in relation to the type of pain
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Comparative analysis of qualitative variables was per-
formed with the χ2 test. For expected numbers < 5,
two-tailed Fisher exact test was then used. Comparisons
of quantitative variables were performed with Mann-
Whitney U-test for independent variables or Wilcoxon
rank test for dependent variables. Analysis of variance
(ANOVA) was implemented for comparisons of higher
numbers of independent variables.
For selected sets of quantitative variables, linear
regression and Pearson correlation coefficients were
calculated. Linear regression equations are presented
only for statistically significant correlations. Single,
outlying data points were excluded from the analysis
based on visual evaluation of distribution plots and
the influence of a given outlying data point on linear
regression slopes.
All statistical analyses were performed with 
STATISTICA 8.0 (StatSoft, Inc. 2008) software with
the significance level set at p < 0.05 for all the tests.
Results
All of the patients in our cohort showed significant
improvement when assessed with the VAS (p < 0.001).
The best outcome was found in patients diagnosed with
NFP (p < 0.001). Worse results were achieved in pa -
tients treated with MCS for HNP (p < 0.001) or for
DP (p = 0.04) (Figs. 1 and 2, Tables 1 and 2).
Ten patients with NFP (90.9%; 95% CI: 62.3-
98.4%) showed at least a good response to stimulation,
i.e. ≥ 50% reduction of pain during follow-up. Per-
centage of improvement was assessed based on VAS
scale scores prior to and three months after surgery.
A very good response (pain reduction by at least 75%)
was achieved in 7 patients (64%; 95% CI: 35.4-84.5%).
Treatment was unsuccessful in one patient (9%; 95% CI:
1.6-37.7%; Fig. 3). 
Age [years] 53.1 (47.1-59.2)
Males 47.8% (29.2-67.0)
Pain type
Neuropathic facial pain* 47.8% (29.2-67.0)
Hemi-body neuropathic pain* 34.8% (18.8-55.1)
Deafferentation pain* 17.4% (7.0-37.1)
Transcranial magnetic stimulation 62.5% (38.6-81.5)
responders (n = 16)
Pain intensity prior to MCS [VAS] 8.3 (8.0-8.6)
Pain intensity with MCS [VAS] 3.4 (2.8-4.0)
Improvement after MCS [% VAS]† 59.3% (52.8-65.7)
Improvement ≥ 50%* 81.8% (61.5-92.7)
Improvement ≥ 75%* 31.8% (16.4-52.7)
Table 1. Cumulative characteristics of the motor cortex stimulation (MCS) group
CI – confidence interval; VAS – visual analogue scale
Data are presented as means (95% CI) or, when marked with an asterisk, as ratio (95% CI). 
*Case of explantation was counted as treatment failure.
†Calculated as (MCS OFF – MCS ON)/MCS OFF
Neuropathic Hemi-body Deafferentation P-value
facial pain neuropathic pain pain 
(n = 11)* (n = 8) (n = 4)
Age [years] 58.4 (51.1-65.6) 48.9 (35.7-62.0) 47.3 (21.0-73.5) 0.232
Males† 18.2% (5.1-47.7) 75.0% (40.9-92.9) 75.0% (30.1-95.4) 0.024
Transcranial magnetic 62.5% (30.6-86.3) 62.5% (30.6-86.3) Not done 1.000
stimulation responders (n = 16)
Pain intensity prior to MCS [VAS] 8.1 (7.6-8.7) 8.6 (8.1-9.0) 8.1 (7.1-7.1) 0.398
Pain intensity with MCS [VAS] 2.6 (1.7-3.4) 4.2 (3.1-5.2) 4.0 (3.4-4.6) 0.013
Improvement after MCS [%VAS]‡ 69.2% (60.6-77.8) 51.3% (40.7-62.0) 50.3% (36.6-64.0) 0.007
Improvement ≥ 50%† 90.9% (62.3-98.4) 62.5% (30.6-86.3) 75.0% (30.1-95.4) 0.113
Improvement ≥ 75%† 63.6% (35.4-84.8) 0% (0.0-32.4) 0% (0.0-49.0) 0.002
Table 2. Comparative characteristics of the group based on the type of pain
MCS – motor cortex stimulation; CI – confidence interval; VAS – visual analogue scale
Data are presented as means (95% CI) or, when marked with†, as ratio (95% CI).
*Case of explantation was counted as treatment failure.
‡Calculated as (MCS OFF – MCS ON)/MCS OFF
Motor cortex stimulation in neuropathic pain
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6.8 7.2 7.6 8.0 8.4 8.8 9.2 9.6
Pain intensity prior to MCS [VAS score]
6.8 7.2 7.6 8.0 8.4 8.8 9.2 9.6
Pain intensity prior to MCS [VAS score]
6.8 7.2 7.6 8.0 8.4 8.8 9.2 9.6
Pain intensity prior to MCS [VAS score]
6.8 7.2 7.6 8.0 8.4 8.8 9.2 9.6
Pain intensity prior to MCS [VAS score]
NFP – neuropathic facial pain; HNP – hemi-body neuropathic pain; DP – deafferentation pain; VAS – visual analogue scale
Fig. 3. Linear regression of the dependency between pain intensity and efficacy of motor cortex stimulation (MCS) treatment in each pain type
Overall: F (1.20) = 2.178; R = 0.31; p = 0.156
HNP: F (1.60) = 0.773; R = 0.34; p = 0.413 DP: F (1.20) = 51.7; R = 0.98; f(x) = –0.59 + 0.135*x; p = 0.019
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NFP: F (1.80) = 2.195; R = 0.46; p = 0.177
In the HNP group, at least a good response to sti -
mulation was achieved in 6 patients (75%; 95% CI:
40.9-92.9%). None of the patients showed a very good
response (95% CI: 0.0-32.4%). Pain reduction by less
than 50% was achieved in 2 patients with spinal cord
injury (25%; 95% CI: 7.1-59.1%; Fig. 3).
All patients with DP of the upper extremity reported
pain reduction. Three of them (75%; 95% CI: 30.1-
95.4%) had a good response to the treatment. None of
the patients showed a very good response (95% CI: 0.0-
49.0%). Pain reduction by less than 50% was achieved in
one patient (25%; 95% CI: 4.6-69.9%, Fig. 3). 
The severity of pain assessed with the VAS scale was
comparable between the groups prior to implantation.
Stimulation resulted in a statistically significant reduc-
tion of pain intensity in all of the groups. The best res -
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ponse (p < 0.05) was achieved in patients with NFP. In
the whole group, as well as in NFP and HNP groups,
we found no relationship between initial pain intensity
and the outcome of treatment. Nonetheless, linear re -
gression analysis revealed a very strong and statistically
significant positive correlation in the DP subgroup
(Table 2).
A good response to rTMS was found in 10 patients.
Six patients did not show any reduction of the pain
intensity. A statistically significant (p = 0.036) differ-
ence was present in the MCS group following rTMS
in the frequency of at least a good response to treatment
for all (95% CI: 72.2-100%) and for 3 patients (95% CI:
18.8-81.2%), respectively. A very good response to
MCS occurred in 3 patients (95% CI: 10.8-60.3%)
from the rTMS responsive group while no patients
(95% CI: 0-39.0%) had a very good response in the
group that did not respond to rTMS (Fig. 4).
Anamnesis length positively correlated with the out-
come in our cohort. This correlation is statistically sig-
nificant (p < 0.001) upon exclusion of a single outlying
data point for a 73-year-old man with 32 years of pain
duration, initial VAS of 8 and 43.8% VAS improvement
after stimulation (Fig. 5).
We were forced to remove the system in one patient
in the NFP group three months after implantation due
to infection; we did not attempt to reimplant it. No other
complications were found.
Discussion
Great suffering of the patients as well as inefficient
pharmacotherapy result in attempts to treat neuropathic
pain with minimally invasive MCS. However, lack of
qualification standards for symptomatic treatment of
neuropathic pain with MCS results in inconsistent and
small observational case series. At first, Meyerson and
Tsubokawa treated post-stroke pain syndromes and neu-
ropathic trigeminalgia with MCS. When qualified 
for surgery with no response to pharmacotherapy, 
MCS might be considered a treatment of choice for
these patients. In the treatment of pain with different
aetiologies, such as deafferentation pain, MCS should
be considered only for cases with previous failures of
other surgical modalities such as dorsal root entry zone
(DREZ)-tomy [14-19].
A qualification process for MCS necessitates a pro -
per diagnosis of neuropathic pain and confirmation that
all pharmacological modalities have been exhausted.
Anamnesis should be at least two years long and pain
intensity should exceed 6 on a 10-point VAS scale. Phar-
macological tests (ketamine test in particular) and rTMS
have prognostic value in the qualification process.
The importance of rTMS as a prognostic factor in
the treatment of neuropathic pain has been confirmed,
but a lack of response to rTMS preoperatively should
not disqualify patients with neuropathic pain from
MCS. Additionally, adulthood should be one of the con-
ditions for surgical treatment with MCS.
Negative prognostic factors for MCS implantation
include paresis or paralysis and complete loss of super-
ficial sensation within the pain region. Atypical facial
pain, personality and psychiatric disorders, epilepsy or
TMS responders TMS non-responders
Fig. 4. Pain intensity (as measured on visual analogue scale, VAS) with and
without stimulation depending on responsiveness to transcranial magnetic sti-
mulation (TMS)
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Fig. 5. Pain reduction on visual analogue scale relative to the length of pain
history. Correlation is statistically significant when one outlying observation
was excluded (73-year-old man with pain duration of 32 years, 8 pts. base-
line pain intensity and 43.8% pain reduction after motor cortex stimulation
[MCS], p < 0.001).
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the presence of another stimulation system are contra -
indications for MCS. Psychological examination is
of crucial importance in order to eliminate any patients
with psychogenic pain syndromes that could imitate neu-
ropathic pain. Intraoperative analysis of somatosensory
or motor evoked potentials is not performed during
implantation of MCS for DP related to avulsion injury;
the identification of relevant cortical regions is based on
MRI and fMRI [20-24], as in our cases.
Pain reduction by ≥ 50% when assessed with the
VAS should be considered as a therapeutic success
although no uniform protocol for treatment efficacy eva l-
uation for patients with neuropathic pain exists. The effi-
cacy of neuropathic pain treatment with MCS varies
from 15 to 90%, relative to the group at hand, with
the best results achieved in the NFP group. Accord-
ingly, the follow-up period may influence the outcome,
as up to 40% of patients lose the positive effect of stim-
ulation over a year [6,13,25-27].
Stimulation parameters during the postoperative
period are programmed in order to achieve the effect
of sub-threshold motor stimulation. The ability to mod-
ulate stimulation amplitude allows the patients to change
it depending on the intensity of pain. The most com-
mon complications of MCS treatment include epilep-
 tic seizures (during initial stimulation programming),
infections, epidural haematoma and skin erosion over
the implant [9,28].
Conclusions
1. Motor cortex stimulation is a safe, reversible sympto-
matic treatment for neuropathic pain of various aetio -
logies.
2. Transcranial magnetic stimulation response is a posi -
tive prognostic factor.
3. Neuropathic facial pain shows the highest response
rate to cortical stimulation while deafferentation pain
has a worse prognosis.
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